Drug Sales Trends for ONEXTON

Annual Sales Revenues and Units Sold for ONEXTON

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
ONEXTON			2021
ONEXTON			2020
ONEXTON			2019
ONEXTON			2018
ONEXTON			2017
ONEXTON			2016
ONEXTON			2015

Market Analysis and Sales Projections for ONEXTON

Introduction to ONEXTON

ONEXTON Gel is a topical medication combining clindamycin phosphate and benzoyl peroxide, indicated for the treatment of acne vulgaris in patients 12 years of age and older. It is marketed by Bausch Health Companies Inc.[1].

Market Context: Acne Drugs Market

The global acne drugs market is a significant segment within the dermatological drugs market. In 2018, this market was valued at approximately $15.45 billion and is projected to grow to $20.48 billion by 2022, with a Compound Annual Growth Rate (CAGR) of 7.3%[3].

Product Overview

ONEXTON Gel contains 1.2% clindamycin phosphate and 3.75% benzoyl peroxide. It is applied topically once daily to the affected areas, avoiding the eyes, mouth, lips, mucous membranes, or areas of broken skin. The treatment is generally recommended for up to 12 weeks, although its use beyond this period has not been evaluated[1].

Market Performance

In the financial reports of Bausch Health Companies Inc., ONEXTON has been mentioned as one of the key products contributing to the company's revenue. For example, in the fourth quarter and full-year 2021 earnings presentation, ONEXTON generated $18 million in revenue, indicating a stable presence in the market[2].

Sales Projections

While specific sales projections for ONEXTON alone are not detailed in the available sources, the overall acne drugs market is expected to continue growing. Here are some key points to consider:

• Global Acne Drugs Market Growth: The market is expected to reach $20.48 billion by 2022, growing at a CAGR of 7.3% from 2018[3].
• Segmented Market: The acne drugs market is segmented into inflammatory and non-inflammatory acne treatments. ONEXTON, being a combination therapy, is likely to benefit from this segmentation as it addresses both types of acne[3].
• Competitive Landscape: ONEXTON competes with other prescription acne drugs such as Solodyn, Epiduo, and Differin. The market dynamics, including the introduction of new products and generic challenges, will influence its sales projections[5].

Patent and Generic Challenges

ONEXTON is protected by five patents, with twenty patent family members in fourteen countries. However, there have been Paragraph IV challenges, indicating interest in generic versions. This could impact future sales as generic competitors may enter the market once the patents expire or are successfully challenged[4].

Financial Indicators

• Revenue Contribution: ONEXTON contributes to Bausch Health's revenue, although the exact figures are not always broken down separately. The company's overall dermatology segment has shown growth, which can be partly attributed to products like ONEXTON[2].
• Market Share: While specific market share data for ONEXTON is not provided, its presence in the market and the growing demand for acne treatments suggest it maintains a significant share within the prescription acne drugs segment[3].

Future Outlook

Given the growing demand for acne treatments and the established presence of ONEXTON in the market, here are some key points for its future outlook:

• Market Growth: The acne drugs market's projected growth will likely benefit ONEXTON, assuming it maintains its market position.
• Generic Competition: The potential entry of generic versions could impact sales, but Bausch Health's efforts to protect its patents and maintain market exclusivity will be crucial.
• Regulatory Environment: Continued regulatory approvals and compliance will be essential for ONEXTON's continued presence in the market.

Key Takeaways

• Market Size and Growth: The global acne drugs market is expected to grow significantly, providing a favorable environment for ONEXTON.
• Product Performance: ONEXTON has a stable revenue contribution to Bausch Health.
• Patent and Generic Considerations: The product faces potential generic competition, which could impact future sales.
• Regulatory and Market Dynamics: Maintaining regulatory approvals and navigating market competition will be critical for ONEXTON's continued success.

FAQs

Q: What is ONEXTON used for? A: ONEXTON Gel is used for the topical treatment of acne vulgaris in patients 12 years of age and older.

Q: What are the active ingredients in ONEXTON? A: The active ingredients are clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%)[1].

Q: How is ONEXTON applied? A: It is applied topically once daily to the affected areas, avoiding the eyes, mouth, lips, mucous membranes, or areas of broken skin[1].

Q: What is the projected growth of the acne drugs market? A: The global acne drugs market is expected to grow at a CAGR of 7.3% from 2018 to 2022[3].

Q: Are there any generic challenges to ONEXTON? A: Yes, there have been Paragraph IV challenges to the patents protecting ONEXTON, indicating potential generic competition[4].

Sources

1. FDA NDA 50-819/S-12: ONEXTON Gel prescribing information.
2. Bausch Health Fourth Quarter and Full-Year 2021 Earnings Presentation.
3. Global Acne Drugs Market Report 2020: ResearchAndMarkets.com.
4. ONEXTON Drug Patent Profile: DrugPatentWatch.
5. Dermatological Drugs Market Forecast 2020-2030: Visiongain.